We used specific antisera and immunohistochemical methods to investigate the subcellular localization and expression of Bcr, Abl, and Bcr-Abl proteins in leukemic cell lines and in fresh human leukemic and normal samples at various stages of myeloid differentiation. Earlier studies of the subcellular localization of transfected murine type IV c-Abl protein in fibroblasts have shown that this molecule resides largely in the nucleus, whereas transforming deletion variants are localized exclusively in the cytoplasm. Here, we demonstrate that the murine type IV c-Abl protein is also found in the nucleus when overexpressed in a mouse hematopoietic cell line. However Invest. 1993Invest. . 92:1925Invest. -1939 
Introduction
Clonal expansion of a hematopoietic stem cell containing a reciprocal translocation between chromosomes 9 and 22 (the Philadelphia translocation [Ph]') characterizes chronic myelogenous leukemia (CML) and subsets of acute leukemia ( 1, 2) . This translocation results in the head-to-tail fusion of variable numbers of 5' exons of the BCR gene on chromosome 22 with the c-ABL gene derived from chromosome 9 (3) (4) (5) . The resultant chimeric gene is transcribed into a hybrid BCR-ABL mRNA in which exon 1 ofc-ABL is replaced by 5' BCR exons. Bcr-Abl fusion proteins (p210 BCR-ABL and p190 BCRABL) are produced; they contain the NH2-terminal 927 (or 902) or 426 amino acids of Bcr and are implicated in the development of CML and Ph '-positive acute leukemia, respectively (3, (6) (7) (8) (9) .
The oncogenic potential of the Bcr-Abl fusion proteins has been validated by their ability to transform hemopoietic progenitor cells in vitro (10) (11) (12) (13) (14) . Furthermore, transgenic mice carrying BCR-ABL constructs develop lymphoid tumors ( 15, 16) , and reconstituting lethally irradiated mice with bone marrow cells infected with retrovirus carrying the gene encoding p21 BCRABL leads to the development ofseveral fatal hematopoietic neoplasms (17) (18) (19) . By exploiting different retroviral constructs, a myeloproliferative syndrome resembling CML can be induced in 50% of the experimental animals; the remaining animals succumb to pre-B leukemia/lymphoma, or tumors of erythroid and macrophage cell types. Taken together, these data provide cogent evidence for BCR-ABL gene participation in leukemogenesis.
Unfortunately, there still remain significant gaps in our understanding of the role of the normal Abl and Bcr proteins, as well as the aberrant p210BCR-ABL and p190BCR-ABL in human hematopoiesis. In this regard, two types of information might be relevant. First, the types of cells that express a particular protein might be informative. Yet, despite the presumed role of Bcr, Abl, and Bcr-Abl in hematopoiesis, little is known about when these proteins are expressed during hematopoietic development. Second, subcellular localization of a protein often provides significant clues to its function, and the transition from the benign state to the fully malignant one might involve a change in subcellular residence. Importantly, such an event has been inferred from experiments with transfected mouse type IV c-ABL. The mammalian c-ABL gene produces two proteins of 145 kD that differ only at their NH2 terminus, de- noted types I and IV c-Abl in mice, and types Ia and lb c-Abl in humans, respectively. As demonstrated by immunohistochemistry, the protein product of normal mouse type IV c-ABL constructs transfected into fibroblasts resides mostly in the nucleus whereas constructs with a small NH2-terminal deletion produce a protein that has been moved to the cytoplasm and whose transforming potential has been fully activated (20) . In this study, we have assessed the subcellular localization and differential expression of Bcr, Abl, and Bcr-Abl proteins in Ph'-positive CML and acute lymphoblastic leukemia (ALL) cell lines, as well as in fresh leukemic and normal samples. We have also exploited a unique p2 l0BCRABL-positive CML line (KBM-5), which lacks the normal chromosome 9 and, hence, the normal c-ABL product. Our 
Methods
Cell lines. We used the CML blastic crisis cell line K562 (Ph '-positive), the promyelocytic leukemia cell line HL-60 (Ph '-negative), the acute myelogenous leukemia cell line KG-I (Ph'-negative) ( Northern analysis. To evaluate the presence of BCR, ABL, and BCR-ABL messages, total RNA was prepared as previously described (23) . Poly(A)+ selected mRNA (4 ug/lane) was then size-separated in 1.1% agarose/ formaldehyde gels, transferred to nitrocellulose filters, and hybridized to 32P-labeled cDNA probes. Preparation of cDNA probes and hybridization conditions used for the Northern analysis have been previously described (24) . The BCR probe was derived from the 0.45 kb EcoRI / Pstl cDNA fragment located at the 5' end of clone K28. This fragment is composed entirely of non-ABL sequences (25) .
The c-ABL probe was derived from an EcoRl /BamHI cDNA fragment corresponding to the most 5' v-ABL hybridizing region (26).
Southern analysis. To evaluate the configuration ofthe BCR gene, DNA was prepared, as previously described (27) (30) , and the amplification was performed for 40 cycles. Detection was performed using the hybridization protection assay, according to methodology identical to that previously used in our laboratory (31 ) . The 5' primer was a 20-mer beginning 65 bases upstream of the c-ABL exon lb/Il junction. The 3' primer used is as previously described (30) . An acridinium ester-labeled oligonucleotide complementary to ABL exon Ib/II junction sequences was synthesized by Gen-Probe (San Diego, CA) (32) . This probe is a 24-mer spanning the splice junction with 14 bases in exon II.
Similarly, to determine the presence of normal BCR message in KBM-5 cells, we amplified normal BCR cDNA using the following primers: BCRa 5'-AAGGCAGCCTTCGACGTCAATAAC-3', BCRb 5 '-GACTTCGGTGGAGAACAGGATGCT-3'. Southern blotting and hybridization with an oligonucleotide probe 5'-ATTGACTGCCTC-CTTCTCTGCCAC-3' was done for detection purposes according to the method of Kawasaki and colleagues (30) .
Immune complex kinase assay. p210CROABL and p1 90BCRABL were detected by exploiting their tyrosine phosphokinase enzymatic activity in the immune complex kinase assay (7) . The antiserum used for this assay was anti-Abl389-403, a rabbit polyclonal serum made against the predicted hydrophilic domains of v-Abl (7). The immune complex kinase assay was performed on 2 X I07 cells. To ensure that the 210 and 190 bands on the gels represented proteins recognized by the anti-Abl serum, rather than background phosphorylation, alternate samples were incubated with anti-Abl serum and blocking cognate peptide (7, 33) .
Fresh cells. Peripheral blood was obtained from five CML Ph' patients in the chronic phase ofthe disease, five patients at blast crisis, two individuals with acute myelogenous leukemia (Ph'-negative), and three normal volunteers. In addition, two bone marrow samples derived from normal donors when marrow was collected for allogeneic transplant served as normal controls. Sample collections were performed at M. D. Anderson Cancer Center (Houston, TX) in accordance with institutional guidelines, and after obtaining informed consent from all participants. Red blood cells were lysed with 1.22% ammonium oxalate (Sigma Immunochemicals, St. Louis, MO), and the white blood cells were washed with PBS. To obtain blasts and granulocytes for immunoblotting, cells from a CML myeloid blast crisis patient were separated on Percoll (Pharmacia Fine Chemicals, Piscataway, NJ) discontinuous gradient, and fractions 1.045 and 1.080 g/ml were collected.
Immune reagentsfor immunofluorescence and immunohistochemistry. For detection of Abl protein, rabbit polyclonal antisera against v-Abl trpE bacterial fusion protein pEX4 (kindly provided by Dr. Owen Witte, Howard Hughes Medical Institute, University of California at Los Angeles) was used (33) . Soluble PEX4 protein for affinity purification ofantisera and blocking purposes was obtained by expressing the PEX4 sequence as part of a bacterial fusion protein, with the Schistosoma japonicum gluthatione S-transferase protein in the glutagene expression system, as previously described (20, 34) . For detection of Bcr protein, two antisera were used: (a) rabbit polyclonal sera against fl-galactosidase/Bcr fusion protein (35) , which was affinitypurified using glutathione S-transferase Bcr fusion protein; and (b) monoclonal antibody against Bcr (7C6), originally described by Dhut et al. (36) (Oncogene Science, Inc. Uniondale, NY). All these antisera have been extensively characterized (33) (34) (35) (36) .
Immunofluorescence. Cells were cytospun on glass slides at a density of 1 x I05 cells/slide. All subsequent steps were carried out at room 1926 temperature. Slides were fixed in 4% paraformaldehyde (Sigma Immunochemicals) in PBS for 10 min. Paraformaldehyde fixed cells were quenched in 0.1 M 2-ethanolamine pH 8.0 (Sigma Immunochemicals) for 5 min, then permeabilized by 0.2% Triton X-100 (Bio-Rad, Richmond, CA) in PBS for 10 min. Cells were then blocked with 5% normal donkey serum (Jackson Immunoresearch Laboratories, West Grove, PA) for 30 min. Primary antibodies were used at a 5-20 ,g/ml concentration. Where indicated, affinity purified anti-pEX4 antiserum was blocked with pEX4 fusion protein by incubation with a 10-fold molar excess of purified protein for 30 min before application to cells. In all experiments, normal rabbit IgG (Jackson Immunoresearch Laboratories) was used as a negative control for anti-pEX4 sera and for the rabbit polyclonal anti-Bcr sera. Isotypic antibody was used as a control for the monoclonal anti-Bcr (7C6) sera. Incubation of primary antibody was for 45 min, followed by extensive washing in PBS. The appropriate secondary antibody (Jackson Immunoresearch Laboratories) was added at a 1:100 dilution for 30 min, after which the cells were washed briefly with PBS and mounted with N-propyl gallate ( (37) in a 5% CO2 incubator at 37°C for 5 d. The cells were then cytospun and processed as described above for immunofluorescence reactions.
Western blotting. Immunoblotting was performed to further assess Bcr-Abl steady state protein levels. Briefly, our procedure was as follows: 2 x I07 Iyophilized cells were lysed in Western sample buffer ( 10 mmol/liter Tris-HCL, 1 mmol/l EDTA, 1% SDS, 5% glycerol, 1% ,B-mercaptoethanol, at final pH of 8.0 containing 0.1% bromo-phenolblue). Boiled and cleared lysates ( 12,000g X 30 min) were fractionated on 8% SDS-polyacrylamide gels. The fractionated proteins were trans- in K562 cells (Fig. 1, lane 1) but not in KBM-5 cells (Fig. 1,  lane 2) . Likewise, PCR analysis followed by HPA did not detect the normal ABL cDNA in KBM-5 cells (data not shown), confirming the absence of these sequences in KBM-5 cells; these data are consistent with the karyotypic analysis ofKBM- 5 Immune complex kinase analysis of p210BCRABL and p190BCR-AEL proteins. The immune complex kinase assay can detect Abl-related proteins because they are enzymatically active as phosphokinases. In this assay, K562 and KBM-5 cells showed p210 BCRABL whereas ALL-I cells showed p 1 90 CR-HL-60 and KG-I cells showed neither p210BCR-ABL nor p190BCR-L (Fig. 2) . (The antiserum used for this assay was anti-Abi389-403 [7] , and we have previously determined that this antibody is unable to detect the normal c-Abl protein [40, 41] (Figs. 3-5 ). K562 cells showed strong immunoreactions localized to the cytoplasm when the anti-pEX4 sera was used (Fig. 3 A) . Cytoplasmic localization of p2 10BCRABL was further confirmed by studying KBM-5 cells (Fig. 5 A) (which lack the normal AbI product) eliminating the possibility of colocalization with the normal counterpart as a 1 2 3 4 5 6 7 8
3",- confounding variable. Similarly, pI90BCRABL was found to be cytoplasmic in ALL-I cells (Fig. 4 A) . Negative controls with normal rabbit sera or with cognate peptide to block anti-pEX4 sera gave no significant fluorescence above background (Figs. 3 C and E, 4 C, and 5 C). Murine c-Abl type IV protein exhibits predominantly nuclear localization in a hematopoietic cell line. In the mouse Ba/F3 cells that overexpress mouse c-Abl type IV protein (the myristoylated form of c-Abl) (22), c-Abl was found predominantly in the nucleus, (Fig. 6 ), but with some staining of the cytoplasm and with several cells exhibiting the prominent plasma membrane staining also seen with other myristoylated Abl proteins (22) . Therefore, murine type IV c-ABL localization in the lymphoblastoid Ba/F3 cells was similarto that previously shown for this protein in fibroblasts (20) . (Fig. 4 B) . In the latter cell line, the anti-Bcr sera would be expected to discern only the normal Bcr protein, and not p190BcRABL, since both of our anti-Bcr antibodies were raised against a BCR region that is deleted from p190BcRARL (33, 41 (Fig. 9, C-E) , as well as the monoclonal anti-Bcr (7C6) reacted (Fig. 10, Cand D) , with decreasing intensity, as the cells progressed from myeloblasts and promyelocytes to myelocytes, metamyelocytes, and mature polymorphonuclear cells. Since CML cells express high levels of p210BCR-ABL, and since both of these antisera detect this protein, these results suggest that the levels of p210BCRIL are higher in earlier stages of myeloid maturation. The signal for Bcr-Abl was cytoplasmic in all of these cells, and there was no apparent change in subcellular localization as Samples derived from bone marrow of normal donors reflected the same pattern as CML cells i.e., the expression of c-Abl (Fig. 9 A) , as well as Bcr (Fig. 10 A) at an early maturational stage, as determined with the use of the anti-pEX4 sera and the monoclonal anti-Bcr (7C6), respectively. However, there was a weaker signal than seen in CML samples. Cells derived from patients with Ph'-negative acute myelogenous leukemia (50-70% blasts), also revealed weakly positive staining for c-Abl and Bcr solely in cells in the early myeloblastic stages (Figs. 9 B and 10 B) . No Abl or Bcr signal was detected in normal control peripheral blood samples which contain no immature myeloid cells (data not shown). The localization was predominantly cytoplasmic in all cells tested for both Bcr and c-Abl. In all experiments with fresh cells in which the antipEX4 sera was used, control experiments with cognate peptide for anti-pEX4 sera, as well as with normal rabbit sera demonstrated no significant signal. Similarly, in experiments in which the monoclonal anti-Bcr (7C6) was used, controls with isotypic antibody consistently demonstrated no significant reactions (data not shown).
To further confirm that a reduction in Bcr-Abl protein levels accompanied myeloid differentiation, immunoblotting was performed. Peripheral blood cells from a CML myeloid blast crisis patient were separated by Percoll gradient. The original sample contained 60% blasts, the fraction at 1.045 g/ml contained 98% blasts, and the fraction at 1.080 g/ml contained 92% neutrophils. As can be seen in Fig. 11 , blast cells (lane 2) had considerable higher levels of Bcr-Abl and Abl proteins as compared to unfractionated leukocytes (lane 1) or neutrophils (lane 3).
In vitro differentiation induction ofHL-60 cells and correlation with the presence ofBcr and Ablproteins. Immunofluorescence techniques using anti-pEX4 sera and monoclonal antiBcr (7C6) sera, demonstrated that DMSO-induced granulocytic maturation of HL-60 cells was accompanied by a significant decrease in Abl and Bcr positivity, respectively (Fig.  12 A, B, D , and E). Control experiments with normal rabbit IgG, and isotypic antibody, respectively, showed no significant fluorescence (data not shown).
Discussion
Subcellular localization ofp210BCRABL p90BcRABL and the normal Bcr and Abl proteins. Abl belongs to a family of tyrosine protein kinase enzymes and, in general, these types of proteins are membrane receptors or cytoplasmic, with the latter presumed to function as signal transducing molecules. In humans, two alternative forms of the normal c-Abl protein exist (type la and lb); they differ in their amino terminal 26 and 44 amino acids (42, 43) . These proteins are highly homologous to the murine c-Abl type I and IV proteins, respectively (44 NH2-and COOH-terminal features that may provide clues to c-Abl subcellular localization and function. For instance, mouse c-Abl IV is myristoylated on the NH2-terminus, whereas c-Abl I is predicted not to be myristoylated (45) . Human c-Abl lb also contains an NH2-terminus glycine residue and a putative myristoylation sequence. Attachment of the myristoyl moiety is involved in targeting cellular proteins to associate with the plasma membrane as exemplified by GagAbl (viral Abl) proteins, which are NH2-myristoylated and distribute at least in part to the cellular membrane (36, 46, 47) . Other studies indicate that it is the carboxy-terminal of c-Abl that is critical in determining subcellular localization. This region contains domains that confer on the mammalian c-Abl protein the ability to bind both DNA (potential nuclear localization) (48) and cytoskeletal actin microfilaments (potential cytoplasmic localization) (20, 49) . In addition, the carboxy terminus of Drosophila Abl dictates proper localization to axons in central nervous system cells (50) .
Recently, Van Etten and colleagues (20) have demonstrated that when the murine type IV c-Abl protein is overexpressed in NIH3T3 fibroblasts, it is found to be largely nuclear, with smaller amounts in cytoplasm, plasma membrane, and associated with the actin cytoskeleton. A COOH-terminal motifthat is unique to c-Abl and not found in Src or other tyrosine (61) . In regard to c-Abl, some antisense experiments (65) implicate a lineage-specific function of c-Abl in myeloid development, so our findings would suggest that this action of Abl is quite early in differentiation. The presence of elevated levels of an aberrant Bcr-Abl protein (which is known to have a high constitutive tyrosine phosphokinase enzymatic activity) may, therefore, account for the discordant maturation (66) and resultant expansion of the myeloid compartment, which is the phenotypic hallmark of chronic phase CML.
